Baxdela 300 mg/10.5mL
delafloxacin meglumine · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Melinta Therapeutics, LLC
Baxdela is a injection, powder, lyophilized, for solution containing delafloxacin meglumine at 300 mg/10.5mL, taken intravenous. Manufactured by Melinta Therapeutics, LLC.
Key Facts
- Brand Name
- Baxdela
- Generic Name
- delafloxacin meglumine
- NDC Code (Product)
70842-102- Manufacturer
- Melinta Therapeutics, LLC
- Strength
- 300 mg/10.5mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- NDA208611
- Marketing Start
- 06/19/2017
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Baxdela used for?
Baxdela contains delafloxacin meglumine. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is Baxdela a controlled substance?
Baxdela is not classified as a controlled substance by the DEA.
What is the generic name for Baxdela?
The generic name for Baxdela is delafloxacin meglumine. There are no other listed brand versions of delafloxacin meglumine.
What is the NDC code for Baxdela 300 mg/10.5mL?
The NDC (National Drug Code) for Baxdela 300 mg/10.5mL is 70842-102, listed by Melinta Therapeutics, LLC.
Other Baxdela Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)